Key facts
- This page summarizes John C. Andres's Form 4 filing for Apyx Medical Corp (APYX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 12 Aug 2024, 16:50.
John C. Andres - 08 Aug 2024 Form 4 Insider Report for Apyx Medical Corp (APYX)
- Reporting relationship
- Director
- Issuer ticker
- APYX
- Reported as of
- 08 Aug 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Aug 2024, 16:50:42 UTC
- Prior SEC filing
- 15 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ John C. Andres
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
John C. Andres filed Form 4 for Apyx Medical Corp (APYX) on 12 Aug 2024.
Change
- Previous filing in this sequence was filed on 15 Aug 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
APYX
transaction
Derivative
Stock Option (Option to Buy)
Award
- Transaction value
- $0
- Shares
- -17,000
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 17,000
- Date
- 08 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,000
- Exercise price
- $1.02
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Issued pursuant to the Issuer's Director Compensation Program as set forth in the Issuer's definitive proxy statement filed with the U.S. Securities and Exchange Commission on June 25, 2024, which provides for the issuance of a stock option to non-employee directors on the date of the Issuer's Annual Meeting of Stockholders. The option vests ratably over a 12-month period and becomes fully vested and exercisable on the first anniversary of the date of grant.